By Kosaku Narioka
Bain Capital is in talks to acquire Mitsubishi Chemical Group's pharmaceutical business in a potential multibillion-dollar deal, a person familiar with the matter said.
The U.S. investment company is in the final stages of negotiations to buy the subsidiary Mitsubishi Tanabe Pharma for possibly more than 500 billion yen, equivalent to $3.21 billion, the person said.
Japanese business daily Nikkei reported earlier that Mitsubishi Chemical had given preferential negotiation rights to Bain Capital for the potential sale of the pharmaceutical unit.
Responding to the Nikkei report, Mitsubishi Chemical in a statement said the company is discussing the ideal business portfolio for the entire company, including the pharmaceutical business, and is going through a portfolio revamp with all options in mind, including possible sales.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
January 21, 2025 00:00 ET (05:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。